| 1 |
25977289 | An increased expression of PI-PLCĪ²1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. | 2015 Nov |
4 |
| 2 |
25307310 | Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. | 2014 Oct 13 |
1 |
| 3 |
23596104 | Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. | 2013 Jun 15 |
1 |
| 4 |
22033492 | Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. | 2012 May |
7 |
| 5 |
21109771 | Synergistic induction of PI-PLCĪ²1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. | 2011 Feb |
5 |
| 6 |
19805378 | Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. | 2009 Sep 29 |
4 |
| 7 |
17625605 | PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. | 2008 Jan |
1 |